On April 26, Axinn partners Matt Becker and Aziz Burgy spoke at ACI’s Paragraph IV Disputes virtual conference.

Matt spoke on a panel entitled, "The Economics and Economy of Drug Patents with ACI’s Hatch-Waxman Series Advisory Board Members: Optimizing Product Selection, Identifying Targets for Litigation and Monetizing IP Portfolios." This breakout session established best practices for cost reduction to enhance predictability for cash flow purposes and evaluated the impact of the conservation of resources on future investment in research and development.

Aziz spoke on a panel entitled, "You Can’t Go Home Again…Or Can You? Establishing Venue in PIV Litigation Post-Valeant v. Mylan." This breakout session provided clarity as practitioners from both branded and generic drug companies revisited the present and anticipated state of the venue quandary.

Click here for more information.